International Journal of Medical and Pharmaceutical Research
2026, Volume-7, Issue 4 : 748-764
Research Article
An Evaluation of Postnatal Patients for Puerperal Pyrexia
 ,
 ,
 ,
Received
June 5, 2026
Accepted
June 25, 2026
Published
July 10, 2026
Abstract

Background: Puerperal pyrexia remains an important cause of maternal morbidity and mortality, particularly in developing countries. Early identification of its risk factors and etiologies is essential for timely intervention and improved maternal outcomes.Objectives: To evaluate the etiological factors, predisposing risk factors, maternal morbidity, mortality, and preventive measures associated with puerperal pyrexia among postnatal women in a tertiary care centre.

Methods: This observational study was conducted over 18 months (August 2022 to February 2024) in the Department of Obstetrics and Gynaecology, Bharati Vidyapeeth (Deemed to be University) Medical College and Hospital, Sangli. A total of 164 postnatal women with puerperal pyrexia were enrolled using convenience sampling. Demographic characteristics, obstetric variables, risk factors, etiologies, and maternal outcomes were recorded and analysed using Epi Info version 7.2.6.0. Statistical analysis included descriptive statistics, Chi-square test, and Student's t-test, with p<0.05 considered statistically significant.

Results: The prevalence of puerperal pyrexia was 16.4%. Most women were aged 20–29 years (50.0%) and were multiparous (46.95%). Lower segment caesarean section was the predominant mode of delivery (57.93%). Mastitis was the most common cause of puerperal pyrexia (25.61%), followed by urinary tract infection (12.80%) and septic thrombophlebitis (12.80%). Anaemia was present in 43.9%, gestational diabetes mellitus in 21.34%, pregnancy-induced hypertension in 39.63%, and immunocompromised status in 18.9% of women. Significant associations with maternal complications were observed for maternal age, PROM/PPROM, place and mode of delivery, gestational diabetes, and immunocompromised status. Sepsis occurred in 3.66% of patients, while the mortality rate was 1.22%.

Conclusion: Puerperal pyrexia continues to be a significant contributor to postpartum morbidity. Caesarean delivery, PROM/PPROM, gestational diabetes, immunocompromised status, and maternal age were important determinants of adverse outcomes. Early diagnosis, strict aseptic obstetric practices, optimal antenatal care, and prompt management of postpartum infections are essential to reduce maternal complications and mortality.

Keywords
INTRODUCTION

Postpartum Pyrexia(PP) is defined as a temperature above 38 °C for 24-hour period or recurring between end of 1st first and 10th day after childbirth. United States Joint Commission on Maternal Welfare further specifies it as a temperature surpassing 38.0 °C on any 2 of 1st 10 days postpartum, excluding 1st 24 hours. 1Temporary fever within 1st24 hours postpartum is disregarded due to its spontaneous resolution, due to lack of clear postpartum cause .2

 

Postpartum pyrexia affects around 5–7% of births globally 3rates differ across regions, with significant impact on maternal health, especially in Sub-Saharan Africa where about 66% of maternal deaths occur. Estimates of PP prevalence in Africa showed disparity, ranging from 64% in one Nigerian study to 2.9% in a Ugandan study in 2018 4,5But prevalence data currently exist for India. Some studies indicated puerperal sepsis as main cause of postpartum pyrexia, accounting for around 4.2% and 14.3% of all maternal deaths, respectively.

 

Infection, or puerperal sepsis, is the main  cause of postpartum fever, as recognized by the World Health Organization 6Increasing rates of puerperal sepsis are attributed to nosocomial infections and increasing antibiotic resistance, posing significant challenges to healthcare systems globally . Previous research proved preventable nature of puerperal sepsis, which is a major contributor to maternal morbidity and mortality in both low and high-income countries . ICausative microorganisms like poly microbial strains with group A b-hemolytic streptococcus, underscore severity of few cases of puerperal sepsis, as seen in an Australian study 7

 

Factors contributing to PP include urinary tract infections (UTIs), surgical wound infections, septic thrombophlebitis, malaria, and mastitis 8Physiological changes during pregnancy, along with birth-related trauma or cesarean procedures, also enhance the susceptibility to postpartum infections [3]. Anemia, prolonged labor, and prolonged premature rupture of membranes (PPROM) and routine unsterilized vaginal examinations during labor, increase risk of sepsis and pyrexia in the postpartum period 9,10

 

In spite of its significance in maternal health, no studies in India directly assessed the burden of PP on maternal morbidity and mortality. Hence, this study was aimed to know risk factors, and etiologies of postpartum pyrexia in our tertiary care setting, facilitating informed actions for its prevention and management.

 

INCLUSION CRITERIA: All postnatal women with puerperal pyrexia who got delivered or referred from outside to this tertiary care center were selected irrespective of their parity, mode of delivery, and with live or dead fetus.

 

EXCLUSION CRITERIA:

The patients were diagnosed with pre-existing infections in the antenatal period.

Patients on steroids

Patients who are not willing to enroll in the study.

Patients who used antibiotics in last 3 days.

Exclusion criteria were assessed mainly through oral history, medical records, and physical and obstetric examination to rule out the conditions mentioned above.

The data of all 164 women was complete. All patients provided consent for the study.

 

Methodology:

Testing for UTI:

All the women were advised to wash hands and to collect urine samplepato. This sample was sent to the laboratory within two hours. The sample was divided into two parts. One part of urine sample was tested for the presence of nitrite, albumin, sugar and pus cells along with colony count. Another part was tested for culture and sensitivity. Treatment was given to all patients having bacteriuria with oral amoxiclav 625mg bd for 7days. Urine culture was repeated 7 days after the completion of treatment. Patients with persistent bacteriuria were treated with Inj. Gentamicin 80mg bd X 5days.

All patients were followed up till one month after delivery and discharge.

 

Parameters assessed:

  1. Demographic data: Age
  2. Parity
  3. Condition of membranes
  4. Mode of delivery
  5. Place of delivery
  6. Aetiology
  7. Duration of labour
  8. Onset of labour
  9. Presence of anemia
  10. Presence of gestational diabetes
  11. Presence of pregnancy induced hypertension
  12. Presence of hydramnios
  13. Presence of immunocompromised status
  14. Complications

 

STATISTICAL ANALYSIS: The data collected was processed in MS Excel 365 and analysis was done using statistical software called EPI INFO free version.  7.2.6.0.P value <0.05, was considered as statistically significant.  Frequencies, percentages were also used.  Mean and SD were used. Chi square test was used to assess categorical parameters. Quantitative measures were compared using T test.

 

Ethical considerations: Permission from the Institutional ethical committee attached to BV(DU)MC&H, Sangli, was taken before conducting the study.  

 

Informed consent was taken from all patients.

 

RESULTS

 

AGE:

50% of the patients were aged 20 to 29 years, 19.51% were aged 30 to 35 years.

AGE

Frequency

Percent

20 to 29

82

50.00%

30 to 35

32

19.51%

Above 35

22

13.41%

Below 19

28

17.07%

Total

164

100.00%

 

PARITY:

46.95% of the patients were multiparous women.

PARITY

Frequency

Percent

GRAND MULTI

28

17.07%

MULTI

77

46.95%

PRIMI

59

35.98%

Total

164

100.00%

 

CONDITION OF MEMBRANES:

56.10% of the patients had intact membranes. PPROM was seen in 21.34% of women.

MEMBRANES

Frequency

Percent

INTACT

92

56.10%

PPROM

35

21.34%

PROM

37

22.56%

Total

164

100.00%

 

MODE OF DELIVERY:

57.93% of the patients underwent LSCS, 9.15% underwent instrumental vaginal delivery.

MODE OF DELIVERY

Frequency

Percent

INSTURMENTAL VAGINAL

15

9.15%

LSCS

95

57.93%

VAGINAL WITH EPI

54

32.93%

Total

164

100.00%

 

PLACE OF DELIVERY:

98.78% of the patients underwent delivery at hospital.

PLACE OF DELIVERY

Frequency

Percent

HOME

2

1.22%

HOSPITAL

162

98.78%

Total

164

100.00%

 

AETIOLOGY:

25.61% of the patients had MASTITIS,12.80% of the patients had UTI, 12.8% of patients had septic thrombophlebitis. The following causes are the foci of infection.

AETIOLOGY

Frequency

Percent

Dengue

15

9.15%

DIC

1

0.61%

Leptospirosis

4

2.44%

Malaria

16

9.76%

MASTITIS

42

25.61%

Others

10

6.10%

Septic thrombophlebitis

21

12.80%

Sub involution

3

1.83%

Typhoid

7

4.27%

UTI

21

12.80%

Vaginal Candidiasis

17

10.37%

Wound gaping

7

4.27%

Total

164

100.00%

 

DURATION OF LABOUR:

29.27% had 8 to 16hrsof labour, 3.05% underwent labour for more than 18 hrs.

DURATION OF LABOUR

Frequency

Percent

16 to 18

16

9.76%

8 to 16 hrs

48

29.27%

More than 18

5

3.05%

Not applicable(LSCS)

95

57.93%

Total

164

100.00%

 

ONSET OF LABOUR:

31.10% of the patients had spontaneous onset of labour.

ONSET

Frequency

Percent

INDUCED

18

10.98%

NA- not applicable- planned LSCS

95

57.93%

SPONTANEOUS

51

31.10%

Total

164

100.00%

 

ANEMIA:

56% of women had anemia.

ANEMIA

Frequency

Percent

NO

92

56%

YES

72

43.90%

Total

164

100.00%

 

GDM:

21.34% of women had GDM.

GDM

Frequency

Percent

NO

129

78.66%

YES

35

21.34%

Total

164

100.00%

 

PIH:

39.63% of women had PIH.

PIH

Frequency

Percent

NO

99

60.37%

YES

65

39.63%

Total

164

100.00%

 

 HYDRAMNIOS:

29.88% of women had hydramnios.

HYDRAMNIONS

Frequency

Percent

NO

115

70%

YES

49

29.88%

Total

164

100.00%

 

IMMUNOCOMPROMISED STATUS:

18.90% of women were immunocompromised (HIV, TB, Malignancies etc)

IMMUNOCOMPROMISED

Frequency

Percent

NO

133

80.83%

YES

31

18.90%

Total

164

100.00%

 

COMPLICATIONS:

87.20% of women had no complications,3.66% of the patients had sepsis.

Death was seen among 1.22% of cases. No complications were seen in 87.2% of patients.

COMPLICATIONS

Frequency

Percent

DEATH

2

1.22%

DIC

3

1.83%

ILEUS

2

1.22%

NIL

143

87.20%

OLIGURIA

4

2.44%

SEPSIS

6

3.66%

SHOCK

4

2.44%

Total

164

100.00%

 

AGE & COMPLICATIONS:

There is significant association between complications & age.

Most of the complications were seen in patients aged above 35 years and below 19 years.

 

COMPLICATIONS

 

AGE

DEATH

DIC

ILEUS

NIL

OLIGURIA

SEPSIS

SHOCK

Total

20 to 29

0

0

0

82

0

0

0

82

30 to 35

0

0

0

32

0

0

0

32

Above 35

1

0

2

8

3

4

4

22

Below 19

1

3

0

21

1

2

0

28

TOTAL

2

3

2

143

4

6

4

164

 

Single Table Analysis

Chi-Squared

df

Probability

99.1156

18

0

 

MEMBRANES AND COMPLICATIONS:

There is significant association between complications &condition of membranes.

Most of the complications were seen in patients with PROM and PPROM.

 

COMPLICATIONS

 

MEMBRANES

DEATH

DIC

ILEUS

NIL

OLIGURIA

SEPSIS

SHOCK

Total

INTACT

0

0

0

89

2

0

1

92

PPROM

1

2

2

24

1

3

2

35

PROM

1

1

0

30

1

3

1

37

TOTAL

2

3

2

143

4

6

4

164

 

Single Table Analysis

Chi-Squared

df

Probability

27.1464

12

0.0074

 

MODE OF DELIVERY & COMPLICATIONS:

There is significant association between complications &mode of delivery.

Most of the complications were seen in patients who underwent LSCS.

 

COMPLICATIONS

 

MODE OF DELIVERY

DEATH

DIC

ILEUS

NIL

OLIGURIA

SEPSIS

SHOCK

Total

INSTURMENTAL VAGINAL

0

1

0

12

2

0

0

15

LSCS

2

2

2

80

1

4

4

95

VAGINAL WITH EPI

0

0

0

51

1

2

0

54

TOTAL

2

3

2

143

4

6

4

164

 

Single Table Analysis

Chi-Squared

df

Probability

18.0207

12

0.1151

 

PLACE OF DELIVERY & COMPLICATIONS:

There is significant association between complications &place of delivery.

2 patients who had home delivery expired.

 

COMPLICATIONS

 

PLACE OF DELIVERY

DEATH

DIC

ILEUS

NIL

OLIGURIA

SEPSIS

SHOCK

Total

HOME

2

0

0

0

0

0

0

2

HOSPITAL

0

3

2

143

4

6

4

162

TOTAL

2

3

2

143

4

6

4

164

 

Single Table Analysis

Chi-Squared

df

Probability

164

6

0

 

ANEMIA & COMPLICATIONS:

There is no significant association between complications &presence of anemia.

 

COMPLICATIONS

 

ANEMIA

DEATH

DIC

ILEUS

NIL

OLIGURIA

SEPSIS

SHOCK

Total

N

0

0

0

1

0

0

0

1

NO

1

3

1

79

2

3

2

91

YES

1

0

1

63

2

3

2

72

TOTAL

2

3

2

143

4

6

4

164

 

Single Table Analysis

Chi-Squared

df

Probability

2.7876

12

0.9969

 

GDM & COMPLICATIONS:

There is no significant association between complications & presence of GDM.

 

COMPLICATIONS

 

GDM

DEATH

DIC

ILEUS

NIL

OLIGURIA

SEPSIS

SHOCK

Total

NO

1

3

2

116

3

3

1

129

YES

1

0

0

27

1

3

3

35

TOTAL

2

3

2

143

4

6

4

164

 

Single Table Analysis

Chi-Squared

df

Probability

12.6789

6

0.0484

 

PIH& COMPLICATIONS:

There is no significant association between complications &presence of PIH.

 

COMPLICATIONS

 

PIH

DEATH

DIC

ILEUS

NIL

OLIGURIA

SEPSIS

SHOCK

Total

NO

0

1

1

92

1

3

1

99

YES

2

2

1

51

3

3

3

65

TOTAL

2

3

2

143

4

6

4

164

 

Single Table Analysis

Chi-Squared

df

Probability

9.4458

6

0.15

 

HYDRAMNIOS & COMPLICATIONS:

There is no significant associationbetween complications &presence of hydramnios.

 

COMPLICATIONS

 

HYDRAMNIONS

DEATH

DIC

ILEUS

NIL

OLIGURIA

SEPSIS

SHOCK

Total

NO

1

3

1

101

3

3

3

115

YES

1

0

1

42

1

3

1

49

TOTAL

2

3

2

143

4

6

4

164

 

Single Table Analysis

Chi-Squared

df

Probability

3.4615

12

0.9913

 

COMPLICATIONS & IMMUNOCOMPROMISED:

There is significant association in complications & immunocompromised status. More complications were seen in patients who are immunocompromised.

 

 

COMPLICATIONS

 

IMMUNOCROMPROMISED

DEATH

DIC

ILEUS

NIL

OLIGURIA

SEPSIS

SHOCK

Total

NO

0

3

2

126

0

0

2

133

YES

2

0

0

17

4

6

2

31

TOTAL

2

3

2

143

4

6

4

164

 

Single Table Analysis

Chi-Squared

df

Probability

59.9429

12

0

 

PARITY & DURATION OF LABOUR:

There is a significant association between parity & duration of labor.

 

DURATION OF LABOUR

 

PARITY

16 to 18

8 to 16 hrs

More than 18

NA

Total

GRAND MULTI

1

4

2

21

28

MULTI

10

25

0

42

77

PRIMI

5

19

3

32

59

TOTAL

16

48

5

95

164


Single Table Analysis

Chi-Squared

df

Probability

11.0001

6

0.0884

 

REFERENCES

  1. Bianco A, Roccia S, Nobile CG, et al. Postdischarge surveillance following delivery: the incidence of infections and associated factors. Am J Infect Control 2013; 41: 549–553. [PubMed] [Google Scholar]
  2. Ely JW, Dawson JD, Townsend AS, Rijhsinghani A, Bowdler NC. Benign fever following vaginal delivery. J Fam Pract. 1996;43(2):146–151. [PubMed] [Google Scholar]
  3. Anbazhagan A, Harper A. Postpartum pyrexia. Obstet, Gynaecol Reproduct Med. 2015;25(9):249–54.
  4. Uhunmwangho EJ, Ojieh GC, Anyanwu RA, Idehen IC, Isibor JO, Turay AA, et al. The incidence and pattern of puerperal pyrexia amongst post-natal women in Benin city, Nigeria. African Journals OnLine. 2012; Available from: https://www.ajol.info/index.php/ijcr/article/download/108348/98170. [Accessed 3 Dec 2019].
  5. Ngonzi J, Bebell LM, Fajardo Y, Boatin AA, Siedner MJ, Bassett IV, et al. Incidence of postpartum infection, outcomes and associated risk factors at Mbarara regional referral hospital in Uganda. BMC Pregnancy Childbirth. 2018;18 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022296. [Accessed 28 Apr 2019]. [PMC free article] [PubMed]
  6. World Health Organization. Trends in maternal mortality 2000 to 2017: estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division.
  7. Zakour NLB, Venturini C, Beatson SA, Walker MJ. Analysis of a Streptococcus pyogenes puerperal Sepsis cluster by use of whole-genome sequencing. J Clin Microbiol. 2012;50(7):2224–2228. doi: 10.1128/JCM.00675-12. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  8. Hamadeh G, Dedmon C, Mozley PD. Postpartum fever. Am Fam Physician. 1995;52(2):531–8. [PubMed]
  9. Dare FO, Bako AU, Ezechi OC. Puerperal Sepsis: a preventable post-partum complication. Tropical Doctor. 1996;28(121):96. [PubMed] [Google Scholar]
  10. Ross C, Arulkumaran S. Postpartum pyrexia. Obstet Gynaecol Reprod Med. 2018;28(6):177–182. doi: 10.1016/j.ogrm.2018.04.001. [CrossRef] [Google Scholar]
Recommended Articles
Research Article Open Access
Diagnostic Performance of Pipelle Endometrial Sampling in Perimenopausal Women with Abnormal Uterine Bleeding: A Prospective Observational Study
2026, Volume-7, Issue 4 : 775-780
Research Article Open Access
The Contributions of Greek and Arab Scholars in the Advancement of Neuroscience: A Comprehensive Analysis
2026, Volume-7, Issue 4 : 711-719
Research Article Open Access
The Correlation between Type 2 Diabetes Mellitus and Hypothyroidism: A Cross-Sectional Study
2026, Volume-7, Issue 1 : 3764-3770
Research Article Open Access
Effect of Coconut Water on Renal Parameters After Dichlorvos Toxicity in Albino Rats
2026, Volume-7, Issue 4 : 737-741
International Journal of Medical and Pharmaceutical Research journal thumbnail
Volume-7, Issue 4
Citations
7 Views
7 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
Creative Commons Attribution License Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
facebook twitter linkedin mendeley research-gate
© Copyright | International Journal of Medical and Pharmaceutical Research | All Rights Reserved